Moderna, Inc. (MRNA) saw its stock price surge 5.13% during intraday trading on Monday. The biotech company's shares gained momentum as investors reacted positively to developments in its product pipeline and favorable analyst sentiment.

The rally is primarily attributed to optimism surrounding Moderna's seasonal influenza vaccine candidate, mRNA-1010. The U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee recently provided unanimous 9-0 support, recommending that the vaccine's benefits outweigh the risks for adults aged 50 and older. While the recommendation is non-binding, the FDA typically follows its advisory panels, with a final regulatory decision expected by early August.

Further bolstering investor confidence, analyst firm Arete significantly raised its price target for Moderna from $185 to $433, well above the consensus target. The company has also been actively repositioning itself as a platform biotechnology firm, recently unveiling new pipeline assets including its in-vivo CAR-T program and appointing a new Chief Commercial Officer to prepare for potential new vaccine launches.